利用新型药物、方法和联合模式实现乙型肝炎病毒的消除
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.
作者信息
Boucle Sebastien, Bassit Leda, Ehteshami Maryam, Schinazi Raymond F
机构信息
Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, 1760 Haygood Drive, Atlanta, GA 30322, USA.
Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, 1760 Haygood Drive, Atlanta, GA 30322, USA.
出版信息
Clin Liver Dis. 2016 Nov;20(4):737-749. doi: 10.1016/j.cld.2016.07.001. Epub 2016 Aug 30.
Abstract
Hepatitis B virus (HBV) causes significant morbidity and mortality worldwide. The majority of chronically infected individuals do not achieve a functional and complete cure. Treated persons who achieve a long-term sustained virologic response (undetectable HBV DNA), are still at high risk of developing morbidity and mortality from liver complications. This review focuses on novel, mechanistically diverse anti-HBV therapeutic strategies currently in development or in clinical evaluation, and highlights new combination strategies that may contribute to full elimination of HBV DNA and covalently closed circular DNA from the infected liver, leading to a complete cure of chronic hepatitis B.
摘要
乙型肝炎病毒（HBV）在全球范围内导致了严重的发病和死亡。大多数慢性感染者无法实现功能性和彻底治愈。实现长期持续病毒学应答（HBV DNA检测不到）的接受治疗者，仍面临因肝脏并发症而发病和死亡的高风险。本综述重点关注目前正在研发或处于临床评估阶段的新型、机制多样的抗HBV治疗策略，并强调可能有助于从感染肝脏中完全清除HBV DNA和共价闭合环状DNA，从而实现慢性乙型肝炎彻底治愈的新联合策略。
相似文献
1
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.利用新型药物、方法和联合模式实现乙型肝炎病毒的消除
Clin Liver Dis. 2016 Nov;20(4):737-749. doi: 10.1016/j.cld.2016.07.001. Epub 2016 Aug 30.
2
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.基于乙型肝炎病毒共价闭合环状 DNA 的失活/抑制或清除的抗乙型肝炎病毒药物的现状与挑战。
Viruses. 2023 Nov 25;15(12):2315. doi: 10.3390/v15122315.
3
Drugs in the Pipeline for HBV.用于乙型肝炎病毒的在研药物。
Clin Liver Dis. 2019 Aug;23(3):535-555. doi: 10.1016/j.cld.2019.04.006. Epub 2019 May 29.
4
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.利用 CRISPR/Cas9 核酸酶靶向乙型肝炎病毒 cccDNA 可有效抑制病毒复制。
Antiviral Res. 2015 Jun;118:110-7. doi: 10.1016/j.antiviral.2015.03.015. Epub 2015 Apr 3.
5
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.长期核苷（酸）类似物治疗慢性乙型肝炎时共价闭合环状 DNA 的减少。
J Hepatol. 2017 Feb;66(2):275-281. doi: 10.1016/j.jhep.2016.08.022. Epub 2016 Sep 14.
6
Latest developments in the treatment of hepatitis B.乙型肝炎治疗的最新进展。
Minerva Gastroenterol Dietol. 2016 Mar;62(1):88-102. Epub 2015 Oct 8.
7
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?如何实现乙肝功能性治愈：停止核苷（酸）类似物，加用干扰素或开发新药？
J Hepatol. 2022 Jun;76(6):1249-1262. doi: 10.1016/j.jhep.2021.11.024.
8
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.基于核苷（酸）类似物治疗期间和治疗后 HBsAg 免疫复合物和 cccDNA 活性分析。
Hepatol Commun. 2021 Nov;5(11):1873-1887. doi: 10.1002/hep4.1767. Epub 2021 Jul 10.
9
Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).消除乙肝病毒共价闭合环状DNA（cccDNA）的抗病毒策略。
Curr Opin Pharmacol. 2016 Oct;30:144-150. doi: 10.1016/j.coph.2016.08.015.
10
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.血清乙肝表面抗原定量可反映肝脏中的乙肝病毒并预测治疗反应。
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1462-8. doi: 10.1016/j.cgh.2007.09.005.
引用本文的文献
1
Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure.用于治愈慢性乙型肝炎（CHB）的乙型肝炎病毒（HBV）核心及衣壳组装调节剂（CAMs）的生物学特性
Glob Health Med. 2023 Aug 31;5(4):199-207. doi: 10.35772/ghm.2023.01065.
2
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.实现慢性乙型肝炎的完全治愈：乙型肝炎病毒的新治疗靶点。
Clin Mol Hepatol. 2022 Jan;28(1):17-30. doi: 10.3350/cmh.2021.0093. Epub 2021 Jul 20.
3
Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator.GLP-26 作为一种有效的乙型肝炎病毒衣壳组装调节剂的疗效、潜在心脏毒性和猴子药代动力学研究。
Viruses. 2021 Jan 15;13(1):114. doi: 10.3390/v13010114.
4
Divergent synthesis of a thiolate-based α-hydroxytropolone library with a dynamic bioactivity profile.具有动态生物活性谱的基于硫醇盐的α-羟基托酚酮文库的发散合成。
RSC Adv. 2019;9(59):34227-34234. doi: 10.1039/c9ra06383h. Epub 2019 Oct 23.
5
Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.一项慢性乙肝患者4年队列抗病毒治疗的长期病毒学和依从性结果
Antivir Ther. 2019;24(8):567-579. doi: 10.3851/IMP3338.
6
Pharmacological plasticity-How do you hit a moving target?药理学可塑性——如何击中移动目标？
Pharmacol Res Perspect. 2019 Nov 21;7(6):e00532. doi: 10.1002/prp2.532. eCollection 2019 Dec.
7
Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses and in Humanized Mice.新型乙型肝炎病毒衣壳组装调节剂诱导强烈的抗病毒反应和在人源化小鼠中。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01701-19.
8
2019 meeting of the global virus network.2019 年全球病毒网络会议。
Antiviral Res. 2019 Dec;172:104645. doi: 10.1016/j.antiviral.2019.104645. Epub 2019 Nov 4.
9
10
Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran.伊朗阿瓦士地区 HIV-1 感染者中 HCV 的流行情况和基因多样性。
BMC Infect Dis. 2019 May 8;19(1):389. doi: 10.1186/s12879-019-4052-x.
本文引用的文献
1
Hepatitis B virus receptors and molecular drug targets.乙型肝炎病毒受体与分子药物靶点。
Hepatol Int. 2016 Jul;10(4):567-73. doi: 10.1007/s12072-016-9718-5. Epub 2016 Mar 15.
2
New therapies for chronic hepatitis B.慢性乙型肝炎的新疗法。
Liver Int. 2016 Jun;36(6):775-82. doi: 10.1111/liv.13086. Epub 2016 Mar 14.
3
Molecular Determinants of GS-9620-Dependent TLR7 Activation.GS-9620 依赖性 TLR7 激活的分子决定因素
PLoS One. 2016 Jan 19;11(1):e0146835. doi: 10.1371/journal.pone.0146835. eCollection 2016.
4
Recent developments in antivirals against hepatitis B virus.乙型肝炎病毒抗病毒药物的最新进展。
Virus Res. 2016 Feb 2;213:205-213. doi: 10.1016/j.virusres.2015.12.014. Epub 2015 Dec 28.
5
Hepatitis B virus therapy: What's the future holding for us?乙肝病毒治疗：我们的未来会怎样？
World J Gastroenterol. 2015 Nov 28;21(44):12558-75. doi: 10.3748/wjg.v21.i44.12558.
6
Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.慢性乙型肝炎病毒感染功能性治愈的治疗策略。
Acta Pharm Sin B. 2014 Aug;4(4):248-57. doi: 10.1016/j.apsb.2014.05.002. Epub 2014 Jun 18.
7
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.富马酸替诺福韦二吡呋酯和聚乙二醇干扰素α-2a 联合治疗可增加慢性乙型肝炎患者乙型肝炎表面抗原丢失。
Gastroenterology. 2016 Jan;150(1):134-144.e10. doi: 10.1053/j.gastro.2015.09.043. Epub 2015 Oct 8.
8
Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.抗乙肝病毒药物：进展、未满足的需求与新希望。
Viruses. 2015 Sep 15;7(9):4960-77. doi: 10.3390/v7092854.
9
A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.核苷（酸）类似物（NA）联合干扰素治疗对比NA单药治疗在HBeAg阳性慢性乙型肝炎中的抗病毒疗效更佳：一项荟萃分析
Int J Environ Res Public Health. 2015 Aug 21;12(8):10039-55. doi: 10.3390/ijerph120810039.
10
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.合成RNA干扰触发因子及其在具有治愈意图的慢性乙型肝炎治疗中的应用。
Antiviral Res. 2015 Sep;121:97-108. doi: 10.1016/j.antiviral.2015.06.019. Epub 2015 Jun 27.
Zotero 插件